FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Olanzapine and Fluoxetine (Symbyax) Capsules
Status: Discontinuation
»Therapeutic Categories: Psychiatry

Eli Lilly and Co. (New 09/25/2017)

Company Contact Information:

Presentation Posting Date Related Information
Olanzapine/Fluoxetine 12mg/25mg (NDC 0002-3232-30) 09/25/2017 Discontinuation of the manufacture of the drug. Four additional approved doses of Symbyax continue to be available the US market.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English